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The World Health Organization (WHO) recently 
advocated raising the CD4+ count threshold for 
initiating antiretroviral therapy (ART) for HIV-
infected adults to 500  cells/µl, from the current 
350 cells/µl.[1] Following previous WHO guidance, the 
current South African (SA) strategy of treating everyone with a CD4+ 
count <350 cells/µl, and all pregnant women and TB patients, has led 
to remarkable achievements, cutting mother-to-infant transmission 
dramatically and increasing life expectancy.[2,3] The question is: should 
SA follow the latest WHO recommendation?
There are uncontested reasons for using antiretrovirals (ARVs) – 
treatment of significant HIV-related immunodeficiency, and prevention 
of transmission of HIV from mother to child and between discordant 
couples.[1] In addition, there is good reason to believe that treating 
more people will result in an overall decrease in HIV transmission 
in the general population. Tantalising evidence from KwaZulu-Natal 
suggests that a decrease in the incidence of HIV is seen even with 
relatively modest levels of ART coverage.[4] Possible benefits of the 
provision of early ART include improved protection against activation 
of tuberculosis and protection from possible long-term consequences 
of HIV-induced inflammation, although there is controversy over 
how significant this protection is.[5,6] There are further concerns that 
the observational studies driving decisions to raise the CD4+ bar did 
not factor in widespread interruptions in ARVs, which are being 
experienced across the country, or the necessity to revert to more toxic 
regimens that include stavudine when newer and safer drugs run out.[7] 
Drug toxicity, resistance and burdens placed on the health system need 
to be weighed carefully against the relatively modest potential benefits.[8]
What are the implications of implementing the new WHO guidelines 
for the SA health system? The main issue is how to find and treat the 
huge pool (over 2 million) of HIV-positive people with a CD4+ count 
<500 cells/µl who would be eligible for ART. SA has taken 10 years to 
put just over 2 million people on treatment.[3] Between 300  000 and 
500  000 people have become infected each year for the past decade. 
Projecting forward, each of these new annual cohorts would need to start 
treatment some years into the future when their CD4+ counts fall below 
the recommended threshold: after 7 years if the threshold is 200 cells/ µl, 
after 5 years if the threshold is 350  cells/µl, and after just 2.5  years if 
the suggested threshold of 500  cells/µl is accepted.[9,10] The number of 
people newly infected with HIV each year has fallen steadily over the last 
decade, and this decline will be registered as a slow decrease in the annual 
requirement for ART initiation over the following decade.
When the CD4+ threshold changes, it is not just the predictable annual 
cohort of symptomatic patients that comes on stream for ART. Each time 
the threshold is raised, large numbers of asymptomatic HIV-positive 
individuals enter the eligible treatment pool: two annual cohorts (of 
600 000 - 1 million individuals) when the threshold is raised from 200 to 
350 cells/µl, and another two and a half annual cohorts (of about 800 000 
individuals) when the threshold is 500 cells/ µl. In all, the last two WHO 
guideline increases will add over 2 million patients (CD4+ count 200 - 
500 cells/µl) to the treatment pool – in addition to the 300 000 - 500 000 
mostly symptomatic (CD4+ count <200 cells/µl) ART-eligible patients 
who need treatment each year. This number includes about 400  000 
HIV-positive pregnant women who will need to start ART each year, 
according to new Department of Health guidelines.
To put this in perspective, the SA health system started a total of 
about 400 000 people on ART last year – while each year, for the past 
5 years, the annual capacity of the system to start people on ART has 
expanded by only about 20%.[2,3,10]
As pressure mounts for the country’s health system to fall in line 
with the global movement to provide ever-earlier access to ART, 
planners should consider designing a response for SA’s globally 
unique burden of disease, its populations with compelling needs (i.e. 
those who are already receiving treatment, and newly symptomatic, 
immunocompromised, pregnant and paediatric patients), and its 
available resources. Rather than adding yet another 1.5 million 
individuals (with CD4+ counts of 350 - 500 cells/µl) into the ART pool, 
a strong case can be made for SA to keep 350 cells/µl as the threshold 
for now. This would allow time to build a system to take care of the 1 
million largely asymptomatic individuals who were added to the ART 
pool when the threshold increased to 350  cells/µl, and the priority 
populations who need all available ART resources. In addition, it would 
give time to resolve the operational issues to ensure uninterrupted 
ART, strengthen the decentralised treatment sites, and ensure better 
retention in care of those already receiving ART.
Using the imaginative systems improvement and decentralised 
approaches that revolutionised the delivery of prevention of mother-to-
child transmission of HIV in this country, SA can then rapidly phase 
in the expanded service to test and treat a much larger population.[11] 
Looking to the future, the SA health system will need to prepare for 
the inevitable move towards provision of chronic ART, irrespective of 
CD4+ count, for the 5 million or so citizens infected with HIV.
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